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Prostate cancer (PC) is an escalating health burden in the western world. A large number of
patients still present with extraprostatic (i.e., T3/T4, No, MOIM1 or any T category and M1 disease
or involved lymph nodes) and therefore incurable disease. Since the work of Huggins in 1940,
there have been no major therapeutic advances and androgen ablation remains the best
treatment option for extraprostatic androgen-responsive PC. Eighty to ninety percent of PC
patients respond well to this form of treatment initially. After a median time of approximately 2
years, however, relapse to an androgen-independent (Al) state occurs, followed by death after a
further median 6 months. Androgen ablation is rarely curative. The major molecular defect in
extraprostatic and Al PC is the inability of PC cells to initiate apoptosis in response to a variety of
stimuli, including different forms of androgen ablation and cytotoxic agents. The balance between
cellular proliferation and cell death is regulated by multiple genes or families of genes through the
cell cycle. The exact mechanisms governing this intricate and complex process are as yet not
fully understood. One family of genes involved in cell survival/death control is the BcA2 gene
family, which consists of homologous proteins that function to regulate distal and crucial
commitment steps of the apoptotic pathway. The Bcl-2 family constitutes both agonists and
antagonists of apoptosis that function at least in part through protein-protein interactions
between various members of the family. The final outcome depends on the relative ratio of death
agonists and antagonists. Bcl-2 expression has been closely associated with the Al phenotype of
PC. Cytotoxic chemotherapy may be used as palliative therapy in Al PC but has not been found
effective. Most chemotherapeutic cytotoxic agents induce apoptosis in cancer cells by direct and
indirect action on the cell cycle. In vitroand in vivo studies have established that Bcl-2 expression
confers an antiapoptotic activity against androgen withdrawal and cytotoxic chemotherapy. It thus
offers a tempting potential target for therapeutic manipulations of PC. - Environ Health Perspect
107(Suppl 1):49-57 (1999). http.//ehpnetl.niehs.nih.gov/docs/1999/Suppl-1/49-57chaudhary/
abstract.html
Key words: Bcl-2family, prostate cancer, apoptosis, therapeutics
Prostate Cancer
Prostate cancer (PC) is the most common
cancer and the second leading cause of
cancer-related death (after lung cancer) in
men. In 1997, the estimated death toll
due to PC in the United States alone was
approximately 41,000 and the number of
newly diagnosed cases exceeded 300,000
(1). Currently, one of every six men in
the United States can expect to develop
PC in his lifetime. PC shortens life
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dramatically, such that an individual
suffering from metastatic PC may lose
approximately 9 to 10 years of life
expectancy (2). More than 90% of PCs
are diagnosed between 45 and 89 years of
age (average, 72 years ofage). Because the
risk of PC bears a strong relationship to
age, the incidence [1 in 10,000 at <39
years ofage to 1 in 6 for men > 80 years of
age (1)] can be expected to rise because
men are living longer than ever before (3).
Other risk factors include family history
(4), higher intake of dietary fat (5,6),
high blood levels of male sex hormones,
and Americans ofAfrican origin. Vitamins
D and E and selenium are suggested to
have a protective effect (7,8), whereas the
role ofvitamin A is controversial.
Pathology of Prostate Cancer
Histopathologically, high-grade prostatic
intraepithelial neoplasia (HGPIN) is
considered the most likely precursor of
invasive PC because of its peripheral zone
location and immunohistochemical
expression ofbiomarkers similar to that of
PC (9). Prostatic intraepithelial neoplasia
is present in 85% of PC samples (10).
Histologically, almost all PCs are adeno-
carcinomas originating from the prostatic
glandular epithelium. The most widely
used system ofgrading PC is the Gleason
system (11,12), which takes into account
the degree ofglandular differentiation of
epithelial cells in relation to stroma at
relatively low magnification. Grades range
from 1 to 5 depending on tumor archi-
tecture, which varies from well differenti-
ated (showing a preserved glandular
pattern) to poorly differentiated (showing
no definite glandular architecture). A
combined Gleason's score or Gleason's
sum (2-10) is determined by adding the
most frequent primary and secondary
pattern ofcellular architecture in a hetero-
geneous tumor.
PC spreads to local as well as distant
sites. Local spread can involve adjacent
viscera including seminal vesicles, ejacula-
tory ducts, and rectum. The most fre-
quent sites ofmetastatic spread are lymph
nodes, bones, and lungs. Less common
sites include bladder, liver, and adrenal
glands (13).
Because of the gravity ofextraprostatic
disease, a screening program designed to
detect PC at a curable stage appears logi-
cal. However, there are limitations with
present screening methods; even after his-
tologic diagnosis has been made, the bio-
logic behavior of individual PC cannot be
predicted. Identification of those cases of
localized PC that require definitive treat-
ment from those in which no treatment is
the appropriate option remains an issue.
At present no definite biologic or molecu-
lar marker exists that can predict the
future clinical behavior of PC while it is
still localized to the prostate [reviewed by
Isaacs (14) and Lalani et al. (15)]. New
genotypic and phenotypic markers are
therefore urgently needed to classify the
disease accurately and to guide its manage-
ment (16). The underlying molecular and
cellular mechanisms governing initiation
and promotion of the malignant and
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metastatic phenotypes are unknown in
PC, although some clues may be gained
from the study ofother cancers. Ofpartic-
ular importance is the need to investigate
factors governing hormone regulation that
may be specific to PC [reviewed by Lalani
et al. (17)].
Clinical Forms of
Prostate Cancer
Prostate cancer can present in a number of
clinical forms. These include latent, local-
ized, locally advanced, and metastatic PC
(Table 1).
Localized Clinically Significant
and Latent Cancer
Part ofthe problem in managing PC lies in
the fact that there is a latent form of the
disease that is equally prevalent in commu-
nities throughout the world. Latent PC is
generally an incidental finding, usually
identified in postmortem studies or in
prostates removed surgically for apparently
benign disease or following prostate-specific
antigen (PSA) testing and imaging-directed
stereotactic biopsy. Latent PC is by defini-
tion small, generally well differentiated, and
the clinical behavior is usually indolent.
This cancer may be found in men as young
as in their 30s and has been reported in
approximately 30% of50-year-olds and up
to 80% of 80-year-olds at postmortem
(18). This is in sharp contrast to clinically
important cancer, which is rare in Asia
(1:100,000) but reaches epidemic propor-
tions in theWest; the highest rates reported
are inAmericans ofAfrican origin (19).
For the clinician the challenge is to
distinguish between patients with localized
disease (T1,2NoM0) that is a) dinically sig-
nificant and that will metastasize if
untreated, usuallyjustifying radical therapy;
b) dinically significant but is an apparently
localized disease with unidentifiable occult
metastases using current imaging tech-
niques in whom there is no curative option
(but these patients may be subjected to rad-
ical therapy in the hope ofcure); and c)
latent cancer that will not affect them dur-
ing their lifetime. There are currently no
clinical or molecular tests to distinguish
between these three groups ofpatients.
Table 1. Clinical manifestations of prostate cancer.
Managementof
ProstateCancer
Whitmore (20) asked, "Is cure possible in
those for whom it is necessary, and is cure
necessary in those for whom it is possible?"
There is no doubt that a large number of
patients require effective treatment for
their disease, whether localized or extrapro-
static. Treatment depends primarily on
stage but also on the patient's age, general
fitness, and comorbidity. Localized PC can
be managed by watchful waiting, radio-
therapy, or radical prostatectomy. During
watchful waiting patients may be assessed
regularly by monitoring serum PSA levels
or by digital rectal examination to deter-
mine disease progression. By following
patients conservatively, the morbidity of
active treatment can be avoided. The mean
age of PC at presentation is 72 years, at
which age death due to intercurrent dis-
eases is greater than that from PC itself.
However, patients in younger age groups
and especially those with high-grade dis-
ease may be considered for active treat-
ment. With improvement in surgical
techniques and increased knowledge ofsur-
gical anatomy of the prostate, radical
prostatectomy has become a safe treatment
for localized PC with apparent positive
long-term results (21). However, it
remains to be proven more effective than
either radiotherapy or watchful waiting.
Radiotherapy is especially used in older
patients and in those presenting with inter-
current illnesses and who are therefore
unsuitable for radical surgery. Patients best
suited for radiotherapy have a low serum
PSA level (<20 ng/ml) and low-grade low-
stage tumors (22). Endocrine (hormone)
therapy is the mainstay of treatment in
patients with locally advanced and/or dis-
seminated metastatic PC. Hormone ther-
apy may take the form of surgical
castration, leutinizing-hormone releasing
hormone analogues (medical castration),
antiandrogens, or a combination of castra-
tion and antiandrogens that blockboth tes-
ticular and adrenal androgens-maximum
androgen blockade. Cytotoxic chemother-
apy in androgen-independent (AI) PCs has
limited success.
Hormone and
Chemoresisance
in ProstateCancer
DeterminantsofTreatmentFailure
in Prost Canmr
Because of the lack of definite curative
therapy for extraprostatic PC, patients
require palliative treatment such as
hormone downregulation and cytotoxic
chemotherapy to alleviate their disease-
related symptoms and improve their gen-
eral well being. These treatments aim to
kill tumor cells in situ by inducing apop-
tosis, or if this cannot be achieved, by at
least keeping them confined to their cur-
rent boundaries by cytostasis. The exact
underlying mechanisms responsible for the
development ofAI and chemoresistance in
PC is unknown.
The normal prostatic epithelium
requires androgens for mitogenesis, as is
also true for prostatic adenocarcinomas.
This is why most PCs respond initially to
androgen ablation therapy, which causes
tumor regression by inhibiting cellular
proliferation and inducing apoptosis (23).
The response is usually short-lived and
results in an AI tumor. AI tumors are usu-
ally more aggressive and show little or no
response to androgen-ablative measures.
As the effects ofandrogen/antiandrogens
are mediated through the androgen recep-
tor (AR), much research effort is focused
on the role ofAR in tumor recurrence
and progression (24), which may be a
consequence ofmultiple genetic and epi-
genetic events, including mutations in
and altered expression of the AR (15).
Mechanisms by which PC cells circum-
vent endocrine therapy have thus far
focused on loss ofAR, amplification of
wild-type AR and clonal expression of
these cells, and mutations ofAR resulting
in either increased transactivation and/or
loss of specificity for steroid hormones
and their antagonists (25-31). Alter-
natively, the defects could occur in the
AR down stream-signaling pathways,
leading to AI in the presence of a normal
AR. Whatever the cause ofAI tumors, the
final clinical outcome will be the uninhib-
ited proliferation of PC cells even after
androgen ablation. AI PCs also bear a
close association with the expression of
cell death inhibitors of the Bcl-2 family
(32-34).
Several cytotoxic agents, alone or in
combination, have been used in the treat-
ment ofAI extraprostatic PC but with lit-
tle benefit (35). Possible explanations for
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Localized prostate cancer Extra prostatic prostate cancer
Latent(clinically unimportant) Locallyadvancedwithout metastases
Significant without local invasion ormetastases (curable) Locallyadvanced with metastases
Significantwith undetected occultmetastases (incurable) Metastases butprimary localized within prostate
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the failure of cytotoxic chemotherapy
include the slow proliferation rate of PC
and the development ofendogenous resis-
tance to apoptosis by cancer cells due to
dysregulated expression of apototic
inhibitors (regulators) such as members of
the Bcl-2family.
Molecular Regulation
ofApoptosis
AnEvolutionaryConserved Ordering
from Caenorhabditiselegans
toMammals
Several diseases are associated with either
impaired or excessive apoptosis including
cancer, autoimmunity, HIV-associated
immunodeficiency, and some neurodegen-
erative disorders (36-38). Apoptosis is an
evolutionary conserved and genetically con-
trolled mechanism through which cells are
eliminated in both health and disease.
Apoptosis constitutes distinct morphologi-
cal and biochemical changes in the cell.
Morphologically, it involves rapid conden-
sation ofchromatin, shrinkage ofcells, and
ultimately formation of membrane-
enclosed apoptotic bodies that are engulfed
by neighboring scavengers (39-42).
Biochemically, there is relocation ofphos-
phatidyl serine from the inner to the outer
aspect ofthe plasma membrane and degra-
dation of double-stranded nuclear DNA,
leading to production ofoligonucleosomal
DNA fragments (Figure 1). The evolution-
ary conserved nature ofgenetic regulation
of this process has become apparent from
studies of C. elegans, a primitive nematode
worm, through Drosophila melanogaster to
mammals. Two important gene families,
the Bcl-2 gene family and the caspase fam-
ily ofcysteine proteases (previously known
as the interleukin-l-,-converting enzyme
family) play key roles in the regulation and
execution of this program. The Bcl-2
fa.mily, which consists of both inhibitors
and promoters'of apoptosis, constitutes
mammalian homologs of ced9, which is an
inhibitor ofapoptosis in C. elegans. ced9
functions upstream of two cell-death pro-
moters, ced4and ced3. During the develop-
ment of C. elegans, 131 of 1090 somatic
cells normally die. However, these cells fail
to die in response to gain of function
mutations in ced9 (43). Mammalian coun-
terparts of ced3 are caspase proteases,
which can cleave a number of specific
death substrates and execute the final stages
ofapoptotic pathways (Figure 2). Recently
Zou et al. (44) identified another death-
promoting protein, apoptotic protease-
activating factor (Apafl), which is
considered a human homolog ofced4.
Bcl-2 Protein Family and
Regulation ofApoptosis
In vitro studies have highlighted the role of
Bcl-2 proteins as important regulators of
the apoptotic pathway in several cell types
(38,45-49). Bcl-2, the prototype of this
family, was discovered by studies of
t(14:18) chromosomal translocations,
which are frequent in non-Hodgkin
lymphomas and follicular lymphomas
(50-52). The name Bcl-2 (B cell lym-
phoma/leukemia gene 2) signifies the close
association ofthis gene to these malignan-
cies in which enhanced expression was ini-
tially believed to arise solely as a result of
these translocations, resulting in the juxta-
position of the Bcl-2 gene to a potent
enhancer element sequence of the IgH
gene. Several genes have been identified
and designated as the Bcl-2family based on
their sequence homology to Bcl-2. These
genes include both positive and negative
regulators ofapoptosis (Table 2). In con-
trast there is only a single homolog, ced9,
in C. elegans.
Sequence analyses ofBcl-2 family pro-
teins have identified up to four evolution-
ary conserved domains, recently named
BHI to BH4 (BH stands for Bcl-2 homol-
ogy domain), as proposed by Oltavi et al.
Table 2. Bcl-2 protein family.
Cell death regulators Reference
Death suppressors
Bcl-2 See text
BcI-Xl Boise etal. (135)
Mcl-i Zhou etal. (136)
Bcl-w Gibson et al. (137)
Al lin et al. (138)
Death promoters
Bax Oltvai et al. (53)
Bak Chittenden etal. (139)
Bad Yang etal. (140)
Bcl-XS Boise et al. (135)
Bik Boyd et al. (141)
Bid Wang et al. (142)
Harakiri Inohara etal. (143)
2 C. elegans
Figure 1. DNA electrophoresis on ethidium bromide-
stained 1.8% agarose gel showing oligonucleosomal
DNA ladder in thapsigargin-treated DU145 prostatic
epithelial cells (lane 3). Gene transfer-mediated con-
stitutive Bcl-2 expression in the same cells resulted
in inhibition of apoptosis and DNA degradation (lad-
dering) (lane 2). Lane 1 shows 100 bp DNA ladder
(DNA marker).
Mammals
Bcl-2family
eat antagonist Death agonists
(Activating and effector)
Apoptosis Apoptosis
Figure 2. Molecularordering of cell death regulators and effectors in C. elegansand mammals(seetext).
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(53). These domains may have functional
significance, allowing Bcl-2 members to act
as either death promoters or death inhi-
bitors. Most Bcl-2 family members have a
stretch ofhydrophobic amino acids at their
carboxy terminal, which is responsible for
localization (anchorage) to membranes of
cellular organelles.
Bcl-2 proteins interact with each other
through homo- and heterodimerization to
regulate apoptosis. For example, Bcl-2 can
form homodimers by interaction with
another molecule of Bcl-2 or a het-
erodimer with a molecule of Bax (53).
These dimerizations are offunctional sig-
nificance. For example, a Bcl-2:Bax het-
erodimer will favor cell survival, whereas a
Bax:Bax homodimer will favor cell death.
Mutations in BH domains can effect
dimerization potential and abrogate nor-
mal function (54-57). There is great
complexity and cell specificity of homo-
and heterodimerizations [reviewed by
Reed (58)].
Biochemical Functions
ofthe Bcl-2 Family Proteins
The Bcl-2 family proteins have been stud-
ied in relation to their localization to intra-
cellular organelles, primarily the outer
mitochondrial membrane (Figure 3A),
A
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B
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nuclear envelope, and endoplasmic reticu-
lum (59,60). A number of theories based
on experimental observations have tried to
explain how Bcl-2 functions as a death reg-
ulator. Initial observations suggested its role
as an antioxidant (61-64), a regulator of
intracellular calcium (65-69), and in trans-
port ofproteins across cellular membranes
e.g., across the nuclear membrane (68,70,
71). Recently it has been proposed that
Bcl-2 regulates activation of caspase pro-
teases (72-79), which are responsible for
the final executionary steps of apoptosis
(Figure 3A, B). There is as yet no evidence
that these functions are a result ofthe direct
action of Bcl-2. These may, however, be
consequences ofBcl-2 action upstream of
these events. In the last 2 years, Bcl-2 func-
tion has been extensively studied in relation
to its regulation ofpermeability transition
(PT) in mitochondria. The induction ofPT
can result in loss ofmembrane potential
(80,81), inhibition ofoxidative phosphory-
lation, generation of reactive oxygen
species, and release of proteins such as
cytochrome c. Cytochrome c normally
resides in the intermembrane space ofthe
mitochondria and on its translocation to
cytosol can induce activation of caspases
(81,82) (Figure 3A, B). Bcl-2 expression
can inhibit the release ofcytochrome cfrom
Bc1-2
Outermitochondrial
membrane
aME
Apaf1
.
, !- Cell death
Active caspase
Figure 3. (A) Bcl-2 and Bax localize to the outer mitochondrial membrane, predominantly at sites where inner and
outer mitochondrial membranes are in contact with each other. Bcl-2 inhibits the release of cytochrome cfrom the
mitochondrial space (between the inner and outer membranes) and stabilizes mitochondrial potential in response
to apoptotic stimuli. (B) Diagrammatic representation of caspase activation. The active form of a caspase is gener-
ated in the presence of cytochrome c, Apafl, Apaf3 and dATP. The protein Apaf3 has not yet been characterized.
P20 and P10 indicated here represent large and small subunits of a caspase. Bcl-2 blocks the release of
cytochrome cfrom mitochondria and prevents the activation ofcaspases.
the mitochondrial space and stabilizes the
mitochondrial potential (AT) in response
to apoptosis-inducing agents, for example,
stauroporine (83). Furthermore, aproposed
pore-forming capability ofBcl-2, BCI-XL,
and Bax in lipid membranes (84-87), simi-
lar to those of the bacterial toxins (e.g.,
diphtheria) and colicins suggests a novel
function for these proteins as channels for
ions, proteins, or both.
Bcl-2 Family Proteins
Determinants of
Chemosensitivity
The survival advantage provided by Bcl-2
contributes not only to the development of
cancer but also to resistance against a wide
variety of anticancer agents including
cyclophosphamide, cisplatin, etoposide
(VP16), mitoxantrone, adriamycin, cytosine
arabinoside, methotrexate, 5-fluorouracil,
thapsigargin, stauroporine, dexamethasone,
and radiation (68,88-95). Bcl-XL, a death
antagonist, also suppresses the apoptotic
effect of a number of cytotoxic agents
(77,94). Inhibition ofapoptosis induced
by a variety of anticancer agents by Bcl-2
and BCl-XL suggests a common potential
pathway (38,77,94,96).
Downregulation of Bcl-2 protein can
lead to a reversal ofchemoresistance, ren-
dering cancer cells sensitive to the cytotoxic
effects of conventional cytotoxic chemo-
therapy (97-100). In contrast, upregula-
tion ofproapoptotic Bcl-2 members, such
as Bax, Bcl-Xs, and Bak, can induce
chemosensitization (101-103).
The function of Bcl-2 is unique
because it does not affect the pharmacoki-
netics of the anticancer drugs. It blocks
the transmission of signals originating
from the damage to the effectors of
apoptosis, allowing cells to survive in the
presence of otherwise lethal damage,
enhancing the chances ofacquiring genetic
alterations and favoring the development
ofa more malignant phenotype.
Role ofApoptos in the
Development and Progression
of ProstateCancer
Normal prostatic glandular cells have a
low proliferation rate (<0.3%/day) that is
efficiently balanced by the same rate of
apoptosis so that there is no net growth
(104). During transformation to HGPIN,
a net growth of malignant cells occurs
because of the disturbance in equilibrium
between cell proliferation and apoptosis.
The growth kinetics of localized PC
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indicate that there is a decrease in cell
death (and no further increase in prolifera-
tion rate as compared to HGPIN) that is
responsible for its continuous growth
(104). A similar situation occurs in
metastatic PCs in which the proliferation
rate is also low (< 3%) (104). These cell
kinetic data provide an explanation as to
why conventional cytotoxic chemotherapy
(which usually targets actively proliferating
cancer cells) fails to kill PC cells and sug-
gests that proliferation-independent thera-
peutic strategies may be more beneficial
for the treatment ofPC.
Androgen ablative therapies are the
mainstay oftreatment in extraprostatic PC.
Androgen ablation has a dual effect i.e.,
inhibiting epithelial cellular proliferation
and promoting apoptosis (105). Kyprianou
et al. (106) demonstrated that castration of
mice bearing PC82 prostatic epithelial cell
xenografts resulted in tumor regression
(106). Histologic analyses revealed a
decrease in the number ofcells undergoing
mitosis and a dramatic increase in the per-
centage ofcells undergoing apoptosis. In
vivo, PC cells possessing the androgen-
sensitive phenotype also show inhibited
proliferation and apoptosis in response to
androgen withdrawal (23). However, as AI
develops, this response to androgen with-
drawal is abolished. Several studies have
demonstrated that androgen ablation does
not induce apoptosis in AI PC cells. A close
association ofthe Bcl-2 family antiapop-
totic protein expression and the develop-
ment ofAI in PC has been found (32,34).
This means that in Al PC, resistance to
apoptotic-inducing cytotoxic chemothera-
peutics is contributed both byslowprolifer-
ation and acquisition of the antiapoptotic
potential owing to the dysregulated expres-
sion of antiapoptotic Bcl-2 homologs.
Therefore, potential measures to overcome
cytotoxic chemoresistance in AI PC can be
achieved either by introducing prolifera-
tion-independent treatment strategies
and/or restoring sensitivity to induce apop-
tosis in cancer cells. Thapsigargin, for
example, could induce apoptotic cell death
independent ofcell proliferation (107,108).
Thapsigargin is a specific inhibitor ofendo-
plasmic reticulum (ER) Ca-ATPase and
results in the depletion ofthe ER pool and
the subsequent signaling of a sustained
influx of extracellular calcium (109).
Agents that could target Bcl-2 or related
antiapoptotic proteins and therefore sensi-
tize cancer cells to undergo apoptosis could
also be useful as new therapeutic modalities
in the management ofPC.
Bcl-2 and Prostate
Cancer Progression
De novo expression of BcI-2 has been
reported in a number of epithelial malig-
nancies including those arising from the
breast, urinary bladder, thyroid, stomach,
lung, intestine, and prostate (32,34,
110-127). In normal prostate and benign
prostatic hypertrophy, Bcl-2 expression is
limited to the androgen-insensitive basal
cells of prostatic glandular epithelium.
Hormone-responsive luminal cells do not
express Bcl-2 (32,34). Krajewska et al.
(115) reported Bcl-2, BCl-XL, and Mcl-1
expression in primary and metastatic PCs.
Higher grade PCs and metastases expressed
these antiapoptotic proteins more often
and with greater intensity than lower grade
tumors. A strong association of Bcl-2
expression and the development ofAI in
PC was reported in 1992 by McDonnel et
al. (34). Colombel et al. (32) reported
strong Bcl-2 expression in Al tumors
obtained from metastatic PC patients after
hormone treatment. Higher expression of
Bcl-2 has also been reported in patients
kept on androgen-ablative treatment com-
pared to a control group (118). These
studies suggest a role for these antiapop-
totic proteins in the progression of PC
towardAI.
In vitro studies on PC cell lines suggest
a role for Bcl-2 in the inhibition of apop-
tosis and progression to AI (33). Raffo et
al. (33) have shown that Bcl-2 transfection
into LNCaP cells (a human androgen-sen-
sitive PC cell line) resulted in the inhibi-
tion of apoptosis in response to serum
(growth factors) withdrawal in contrast to
apoptotic cell death in controls. Moreover,
Bcl-2 expression provided a growth advan-
tage in the absence of androgens i.e.,
LNCaPlBcl-2 transfectant xenografts in
nude mice continued their growth after
castration, whereas tumors formed by the
control transfectant regressed after castra-
tion and showed evidence ofapoptotic cell
death (33). McConkey et al. (95) reported
close association of de novo Bcl-2 expres-
sion with acquisition of the metastatic
phenotype by LNCaP sublines derived by
orthotopic implantation into rat prostates.
These Bcl-2-expressing sublines were sig-
nificantly resistant to adriamycin and
thapsigargin-induced apoptosis (95). We
have observed a similar chemoresistance
against adriamycin and thapsigargin in the
Bcl-2 transfectants ofthe DU145 prostatic
epithelial cell line expressing high levels of
Bcl-2 protein (128). Enforced Bcl-2
expression in these cells altered the expres-
sion ofother cell-cycle and cell-death reg-
ulators includingp53 and proliferating cell
nuclear antigen.
Studies utilizing antisense oligo-
nucleotides directed against BcI-2 mRNA
demonstrated the development ofchemo-
sensitivity to chemical agents in otherwise
chemoresistant cells (97-99). A similar
approach using ribozymes (enzyme cou-
pled antisense nucleotides) against Bcl-2
and BCI-XL has also been reported to favor
apoptosis (129,130). Taken together, these
observations suggest that ectopic BcI-21Bcl-
XL expression confers a death-resistant phe-
notype and imparts an ability to inhibit the
initiation of the apoptotic cascade in
response to several stimuli including chem-
ical agents and radiation (131).
Potential forTherapeutic
Intervention
Several studies, some ofwhich have been
cited in this review, demonstrated that
inhibition ofsome ofthe death antagonists
ofthe Bcd-2 family can significantly poten-
tiate apoptosis. This offers hope in devel-
oping potential therapeutic modalities to
combat cancers in general and PC in par-
ticular. There are several other potential
mechanistic targets involving Bcl-2 that
may offer additional hope, including anti-
sense strategies utilizing oligonucleotides or
ribozymes against Bcl-21Bcl-XL mRNA.
Other potential mechanistic targets include
therapies to alter Bcl-2/Bcl-XL protein
configuration inhibiting homo- and
heterodimerization, for example, phospho-
rylating Bcl-2, rendering it nonfunctional
(132,133), and upregulating the expression
ofdeath promoters e.g., Bax, Bak, etc.
Antisense strategies using anti-Bcl-2
oligonucleotides or ribozymes may abolish
Bcl-2 expression by targeting Bcl-2 mRNA
and are effective at least in vitro (129,130).
Another mechanism to prevent Bcl-2-medi-
ated inhibition ofcell death is to convert
Bcl-2/Bd-XL protein configuration to non-
functional forms. Phosphorylation ofBcl-2
renders it nonfunctional as a death
inhibitor (132,133) and abolishes hetero-
dimerization ofBcl-2 with death promoter
partners, allowing death promoters to func-
tion uninhibited (134). Cytotoxic agents,
for example, taxol, vinblastine, and vin-
cristine result in phosphorylation and inac-
tivation ofBcl-2 and can lead to apoptotic
cell death in Bcl-2-expressing cells, includ-
ing those of the prostate (132,133).
Furthermore, selective upregulation of
death promoters (e.g., Bax, Bak) through
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gene therapy strategies may sensitize the
cancer cells to conventional cytotoxics.
Theoretically it is possible to design an
approach utilizing a combination of gene
therapy and chemotherapy that would
effectively upregulate a death promoter via
gene therapy and inhibit death suppression,
such as offered by Bd-2, by chemotherapy-
induced phosphorylation. There are many
challenges that need to be addressed before
such therapies are realized. For example,
thapsigargin can cause significant toxicity,
thus limiting its use. Denmeade and Isaacs.
(107) have attempted to address this by
using an inactive prodrug form ofthapsi-
gargin that is enzymatically activated by
tissue(prostate)-specific enzymes.
Summary
Current research into the molecular
mechanism governing the cellular rheostat
(cell growth/cell death) is unraveling a fas-
cinating and complex array of molecules
that both govern and regulate the balanced
state. Future therapies will target specific
molecules or signaling pathways by utiliz-
ing combination therapies. The exciting
progress made in basic PC research offers
opportunities in PC management.
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